Long-lasting persistence of integrase resistance mutations in HIV-2-infected patients after raltegravir withdrawal

Antiviral Therapy

Volumn 16, Issue 6, 2011, Pages 937-940

  Charpentier, Charlotte ^a,b   Larrouy, Lucile ^a,b   Matheron, Sophie ^a,b   Damond, Florence ^a,b   Delelis, Olivier ^c   Mouscadet, Jean François ^c   Campa, Pauline ^d   Chêne, Geneviève ^e   Brun Vézinet, Françoise ^a,b   Descamps, Diane ^a,b  

^a BICHAT HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c Ecole Normale Superieure de Cachan   (France)

^d HÔPITAL SAINT ANTOINE   (France)

^e INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

RALTEGRAVIR;

ARTICLE; CASE REPORT; DRUG WITHDRAWAL; GENE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; INTEGRASE GENE; MOLECULAR EVOLUTION; MUTANT; NONHUMAN; PRIORITY JOURNAL; VIRUS RESISTANCE;

DRUG RESISTANCE, VIRAL; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV REVERSE TRANSCRIPTASE; HIV-2; HUMANS; MUTATION; PYRROLIDINONES; SALVAGE THERAPY; VIRAL LOAD; WITHHOLDING TREATMENT;

EID: 80052668107     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1826     Document Type: Article

References (15)

1. Roquebert B, Damond F, Collin G, et al. HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro. J Antimicrob Chemother 2008; 62:914-920.
2. Roquebert B, Blum L, Collin G, et al. Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimen. AIDS 2008; 22:2045-2046.
3. Charpentier C, Roquebert B, Delelis O, et al. Hot spots of integrase genotypic changes leading to HIV-2 resistance to raltegravir. Antimicrob Agents Chemother 2011; 55:1293-1295.
4. Salgado M, Toro C, Simón A, et al. Mutation N155H in HIV-2 integrase confers high phenotypic resistance to raltegravir and impairs replication capacity. J Clin Virol 2009; 46:173-175.
5. Wirden M, Simon A, Schneider L, et al. Raltegravir has no residual antiviral activity in vivo against HIV-1 with resistance-associated mutations to this drug. J Antimicrob Chemother 2009; 64:1087-1090.
6. Hatano H, Lampiris H, Fransen S, et al. Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy. J Acquir Immune Defic Syndr 2010; 54:389-393.
7. Damond F, Collin G, Descamps D, et al. Improved sensitivity of human immunodeficiency virus type 2 subtype B plasma viral load assay. J Clin Microbiol 2005; 43:4234-4236. (Pubitemid 41129736)
8. Charpentier C, Jenabian MA, Piketty C, et al. Dynamics of enfuvirtide resistance mutations in enfuvirtide-experienced patients remaining in virological failure under salvage therapy. Scand J Infect Dis 2011; 43:373-379.
9. Rowley CF, Boutwell CL, Lee EJ, et al. Ultrasensitive detection of minor drug-resistant variants for HIV after nevirapine exposure using allele-specific PCR: clinical significance. AIDS Res Hum Retroviruses 2010; 26:293-300.
10. Canducci F, Barda B, Ceresola E, et al. Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption. Clin Microbiol Infect 2010; doi:10.1111/j.1469-0691.2010.03375.x.
11. Ferns RB, Kirk S, Bennett J, Williams I, Edwards S, Pillay D. The dynamics of appearance and disappearance of HIV-1 integrase mutations during and after withdrawal of raltegravir therapy. AIDS 2009; 23:2159-2164.
12. Marchant D, Neil SJ, McKnight A. Human immunodeficiency virus types 1 and 2 have different replication kinetics in human primary macrophage culture. J Gen Virol 2006; 87:411-418. (Pubitemid 43169269)
13. Andersson S, Norrgren H, da Silva Z, et al. Plasma viral load in HIV-1 and HIV-2 singly and dually infected individuals in Guinea-Bissau, West Africa: significantly lower plasma virus set point in HIV-2 infection than in HIV-1 infection. Arch Intern Med 2000; 160:3286-3293.
14. Fransen S, Gupta S, Danovich R, et al. Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways. J Virol 2009; 83:11440-11446.
15. Beerenwinkel N, Daumer M, Sing T, et al. Estimating HIV evolutionary pathways and the genetic barrier to drug resistance. J Infect Dis 2005; 191:1953-1960. (Pubitemid 40705404)